Logo image of IBIO

IBIO INC (IBIO) Stock Fundamental Analysis

USA - NASDAQ:IBIO - US4510337086 - Common Stock

1.09 USD
-0.12 (-9.92%)
Last: 11/19/2025, 2:56:45 PM
1.1299 USD
+0.04 (+3.66%)
Pre-Market: 11/20/2025, 8:55:53 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IBIO. IBIO was compared to 533 industry peers in the Biotechnology industry. IBIO has a bad profitability rating. Also its financial health evaluation is rather negative. IBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBIO has reported negative net income.
IBIO had a negative operating cash flow in the past year.
IBIO had negative earnings in each of the past 5 years.
IBIO had a negative operating cash flow in each of the past 5 years.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

IBIO has a Return On Assets of -79.26%. This is in the lower half of the industry: IBIO underperforms 66.23% of its industry peers.
The Return On Equity of IBIO (-123.50%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.26%
ROE -123.5%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
IBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -20.91, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IBIO (-20.91) is worse than 84.62% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that IBIO is not too dependend on debt financing.
IBIO has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: IBIO underperforms 60.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -20.91
ROIC/WACCN/A
WACC8.76%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.59 indicates that IBIO should not have too much problems paying its short term obligations.
IBIO has a worse Current ratio (1.59) than 81.05% of its industry peers.
IBIO has a Quick Ratio of 1.59. This is a normal value and indicates that IBIO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IBIO (1.59) is worse than 80.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.59
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.07% over the past year.
The Revenue has grown by 77.78% in the past year. This is a very strong growth!
The Revenue for IBIO have been decreasing by -24.59% on average. This is quite bad
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
IBIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.56% yearly.
EPS Next Y78.88%
EPS Next 2Y36.84%
EPS Next 3Y22.08%
EPS Next 5Y11.54%
Revenue Next Year-37.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

IBIO's earnings are expected to grow with 22.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3Y22.08%

More info and screens

0

5. Dividend

5.1 Amount

IBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IBIO INC

NASDAQ:IBIO (11/19/2025, 2:56:45 PM)

Premarket: 1.1299 +0.04 (+3.66%)

1.09

-0.12 (-9.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)02-09 2026-02-09
Inst Owners16.45%
Inst Owner Change11.43%
Ins Owners3.14%
Ins Owner Change0%
Market Cap22.07M
Revenue(TTM)400.00K
Net Income(TTM)-18.38M
Analysts86
Price Target4.2 (285.32%)
Short Float %12.65%
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.87%
Min EPS beat(2)-50.12%
Max EPS beat(2)-31.61%
EPS beat(4)1
Avg EPS beat(4)-19.5%
Min EPS beat(4)-50.12%
Max EPS beat(4)6.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-19.45%
EPS NQ rev (1m)33.87%
EPS NQ rev (3m)48.75%
EPS NY rev (1m)32.05%
EPS NY rev (3m)71.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-68.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55.18
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.02
BVpS0.73
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.26%
ROE -123.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.06%
Cap/Sales 4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.59
Altman-Z -20.91
F-Score5
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)216.31%
Cap/Depr(5y)243.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y78.88%
EPS Next 2Y36.84%
EPS Next 3Y22.08%
EPS Next 5Y11.54%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A
Revenue Next Year-37.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
EBIT growth 1Y-80.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.52%
OCF growth 3YN/A
OCF growth 5YN/A

IBIO INC / IBIO FAQ

What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IBIO.


What is the valuation status of IBIO INC (IBIO) stock?

ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.


Can you provide the profitability details for IBIO INC?

IBIO INC (IBIO) has a profitability rating of 0 / 10.


Can you provide the financial health for IBIO stock?

The financial health rating of IBIO INC (IBIO) is 2 / 10.


Can you provide the expected EPS growth for IBIO stock?

The Earnings per Share (EPS) of IBIO INC (IBIO) is expected to grow by 78.88% in the next year.